The Diastolic Heart Failure (HFpEF) drugs in development market research report provides comprehensive information on the therapeutics under development for Diastolic Heart Failure (HFpEF), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Diastolic Heart Failure (HFpEF). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Diastolic Heart Failure (HFpEF) and features dormant and discontinued products.
GlobalData tracks 46 drugs in development for Diastolic Heart Failure (HFpEF) by 35 companies/universities/institutes. The top development phase for Diastolic Heart Failure (HFpEF) is preclinical with 13 drugs in that stage. The Diastolic Heart Failure (HFpEF) pipeline has 44 drugs in development by companies and two by universities/ institutes. Some of the companies in the Diastolic Heart Failure (HFpEF) pipeline products market are: Bristol-Myers Squibb, Renova Therapeutics and AstraZeneca.
The key targets in the Diastolic Heart Failure (HFpEF) pipeline products market include Glucagon Like Peptide 1 Receptor, Myosin, and Sodium/Glucose Cotransporter 2.
The key mechanisms of action in the Diastolic Heart Failure (HFpEF) pipeline product include Glucagon Like Peptide 1 Receptor Agonist with three drugs in Pre-Registration. The Diastolic Heart Failure (HFpEF) pipeline products include nine routes of administration with the top ROA being Oral and ten key molecule types in the Diastolic Heart Failure (HFpEF) pipeline products market including Small Molecule, and Gene Therapy.
Diastolic Heart Failure (HFpEF) overview
Diastolic heart failure, also known as heart failure with preserved ejection fraction, is a condition in which the heart’s main pumping chamber becomes stiff and unable to fill properly. One of the two types of left-sided heart failure is diastolic heart failure. Main causes include high blood pressure, diabetes, coronary artery disease, and obesity. Untreated diastolic heart failure has the potential to be fatal.
For a complete picture of Diastolic Heart Failure (HFpEF)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
